PremiumCompany AnnouncementsKorro Bio Announces Strategic Workforce Reduction Plan Korro Bio initiated with an Overweight at Cantor Fitzgerald Korro Bio initiated with an Overweight at Cantor Fitzgerald PremiumThe FlyKorro Bio price target lowered to $95 from $105 at RBC Capital Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities Korro Bio reports FY24 EPS ($9.37), consensus ($9.73) PremiumThe FlyKorro initiated with Outperform into 2025 catalysts at Oppenheimer Korro Bio initiated with an Outperform at Oppenheimer Why Korro Bio (KRRO) Should Be on Your Investment Radar 
